查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837228

按適應症、技術平台、給藥途徑、分銷管道和最終用戶分類的治療性疫苗市場—2025-2032年全球預測

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療性疫苗市場規模將達到 746.5 億美元，複合年成長率為 10.72%。

關鍵市場統計數據
基準年2024年 330.5億美元
預計年份：2025年 366億美元
預測年份 2032 746.5億美元
複合年成長率 (%) 10.72%

一個整合科學進步、監管變化和相關人員期望的策略框架，旨在指導治療性疫苗領域的決策者。

在科學進步和不斷變化的商業性格局的驅動下，治療性疫苗領域正在經歷一場變革。抗原發現、免疫調節和遞送技術的最新進展，已使治療性疫苗從一項小眾科學研究發展成為涵蓋癌症、感染疾病、自體免疫疾病和神經系統疾病等多種適應症的策略性療法。本導言概述了影響研發人員、製造商和相關人員近期策略重點的核心科學原理、法規環境和相關人員期望。

臨床醫師和經營團隊正面臨一個複雜的環境：精準免疫標靶技術日益成熟，同時，包括核酸構建體、病毒載體和細胞製劑在內的先進平台技術也不斷發展。同時，監管機構也正在完善療效終點、真實世界證據整合和適應症核准機制的證據路徑，這些都將影響產品開發時間表和上市策略。綜上所述，這些動態變化既帶來了機遇，也帶來了責任：設計能夠證明持續臨床效用的臨床試驗，投資於可擴展的生產，並製定能夠體現患者和醫療保健系統長期價值的定價和准入模式。

因此，要理解治療性疫苗，需要從多角度出發：適應症特異性生物學、平台能力、給藥和分發實際情況，以及相關人員接受度的經濟影響。本執行摘要闡述了這個觀點，並為讀者深入分析產業轉型、政策影響、市場區隔影響、區域動態、競爭格局以及可操作的建議奠定了基礎。

重大的技術、監管和生產變革正在重新定義治療性疫苗的研發路徑和商業策略。

治療性疫苗領域正再形成一系列變革性轉變，這些轉變將改變產品的研發、生產、監管和商業化方式。 mRNA和自擴增RNA平台的技術加速發展，以及脂質奈米顆粒遞送技術的改進和抗原篩選方法的進步，正在縮短從發現到首次人體接種的時間。同時，病毒載體工程和全細胞或樹突細胞策略正在拓展治療範圍，使其覆蓋先前難以攻克的疾病，尤其是在腫瘤學和複雜感染疾病。這些平台的進步使得更精準的免疫編程和聯合治療策略成為可能，例如將疫苗與查核點抑制劑或標靶治療結合，從而提高療效。

法律規範也在同步調整，以適應適應性試驗設計、替代終點和以有意義的臨床結果為重點的加速路徑。支付方和醫療系統日益要求強力的價值證明，包括療效的持久性和後續成本抵消，這促使研發人員從研發的早期階段就將衛生經濟學和結果研究納入其中。此外，模組化設施、一次性生物製程和分散式生產模式等製造創新降低了規模化生產的技術門檻，同時也提高了對供應鏈韌性和品質保證的期望。

總而言之，這些轉變正在推動一種新的產業架構的形成，在這種架構中，多學科協作、靈活的監管互動和策略性的製造投資決定了競爭優勢。那些能夠將科學抱負與切實可行的商業化計劃和相關人員參與相結合的組織，將更有能力把免疫學方面的進展轉化為對患者有意義的影響和永續的商業性成果。

美國關稅政策將於2025年生效，其變化將如何影響治療性疫苗開發商的供應鏈策略、生產在地化和採購慣例？

美國2025年實施的關稅政策變化所帶來的累積效應，為治療性疫苗的相關人員在採購、生產和供應決策方面帶來了新的考量。某些生技藥品原料和組件的進口關稅提高，推高了關鍵原料的成本，包括用於奈米顆粒載體的脂質、質體DNA生產原料以及病毒載體生產中使用的特殊試劑。因此，供應鏈規劃正轉向更加重視供應商多元化和策略性庫存管理，以降低價格波動和潛在的運輸中斷風險。

為因應關稅帶來的成本壓力，一些開發商正加快推動生產營運在地化，並認證國內合約開發和受託製造廠商，以減輕跨境關稅的影響。這一轉變影響了資本配置和前置作業時間管理，因為建造或改造設施需要大量的營運規劃。此外，採購團隊正在重新評估籌資策略和總落地成本分析，以納入關稅的影響，以及運輸、低溫運輸物流和監管合規等方面的成本。

監管機構和商業相關人員也積極應對這些貿易政策的影響。支付方和合約實體正在更嚴格地審查成本投入，這凸顯了早期進行衛生經濟建模和透明的供應成本核算的重要性。政策的不確定性促使各方更加關注多源採購、關鍵投入的策略性儲備以及研發人員和生產合作夥伴之間的風險共擔機制。最終，2025年的關稅情況凸顯了建立具有韌性的供應鏈、採取積極主動的籌資策略以及製定符合政策的商業計劃對於保障專案進度和患者用藥的重要性。

將適應性生物學、平台選擇、給藥途徑、分銷管道和最終用戶實際情況與策略專案設計聯繫起來的深度細分洞察

針對不同細分市場的動態變化驅動著治療性疫苗計畫在臨床、監管和商業策略上的差異化，適應症、平台、給藥途徑、分銷管道和最終用戶等因素都會影響研發方案的選擇。不同適應症的研發重點也有顯著差異。在自體免疫疾病領域，我們將重點放在那些以抗原特異性耐受性和免疫調節為優先事項的疾病，例如紅斑性狼瘡、多發性類風濕性關節炎、類風濕性關節炎和第1型糖尿病；在感染疾病領域，我們優先關注鉅細胞病毒（CMV）、肝炎病毒、愛滋病毒（HIV） 、人類乳突病毒（HPV）和流感病毒等病原體，並將徹底清除病毒和持久控制作為核心終點；在神經系統疾病領域，我們致力於阿茲海默症、肌萎縮側索硬化症、癲癇和帕金森氏症，並將血腦障壁穿透和神經發炎調節作為關鍵的科學挑戰。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新興的基於mRNA的治療性疫苗平台，針對個人化腫瘤新抗原以增強免疫抗原性
  • 利用奈米顆粒載體整合新型佐劑遞送系統以增強疫苗誘發的免疫反應
  • 開發結合治療性疫苗和免疫查核點抑制劑的聯合治療以克服腫瘤抗藥性
  • 將人工智慧融入表位預測工作流程，以加速候選疫苗的設計。
  • 利用 CRISPR 基因編輯技術擴增預製同種異體樹突細胞疫苗，以遞送抗原
  • 基於IND和BLA框架的治療性疫苗加速核准監管路徑的演變
  • 探索異源初免-加強免疫策略以提高疫苗介導免疫的持久性和擴散性
  • 策略性生物技術聯盟增加大型製藥公司對治療性疫苗研發管線的投資

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的治療性疫苗市場

  • 自體免疫疾病
    • 狼瘡
    • 多發性硬化症
    • 類風濕性關節炎
    • 1型糖尿病
  • 癌症
    • 乳癌
    • 子宮頸癌
    • 大腸直腸癌
    • 黑色素瘤
    • 攝護腺癌
  • 感染疾病
    • CMV
    • 肝炎
    • HIV
    • HPV
    • 流感
  • 神經系統疾病
    • 阿茲海默症
    • 肌萎縮側索硬化症
    • 癲癇
    • 帕金森氏症

9. 治療性疫苗市場－技術平台

  • 樹突狀細胞
  • DNA
    • 質體
  • 胜肽
  • RNA
    • mRNA
    • 自擴增RNA
  • 病毒載體
    • 腺病毒
    • 慢病毒
    • 牛痘病毒
  • 全細胞

第10章 依給藥途徑分類的治療性疫苗市場

  • 皮內注射
  • 肌肉注射
  • 靜脈
  • 皮下

第11章 按分銷管道分類的治療性疫苗市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的治療性疫苗市場

  • 診所
  • 醫院
  • 研究所

第13章 各地區治療性疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的治療性疫苗市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國治療性疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Moderna, Inc.
    • BioNTech SE
    • Bavarian Nordic A/S
    • Agenus Inc.
    • Inovio Pharmaceuticals, Inc.
    • Dendreon Pharmaceuticals LLC
    • GeoVax Labs, Inc.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market is projected to grow by USD 74.65 billion at a CAGR of 10.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.05 billion
Estimated Year [2025] USD 36.60 billion
Forecast Year [2032] USD 74.65 billion
CAGR (%) 10.72%

A strategic framing that synthesizes scientific progress, regulatory shifts, and stakeholder expectations to orient decision-makers in the therapeutic vaccines sector

The therapeutic vaccines landscape is at an inflection point driven by converging scientific advances and evolving commercial dynamics. Recent progress in antigen discovery, immune modulation, and delivery technologies has transformed therapeutic vaccines from a niche scientific pursuit into a strategic modality across oncology, infectious disease, autoimmune disorders, and neurological indications. This introduction frames the core scientific rationale, regulatory environment, and stakeholder expectations that collectively shape near-term strategic priorities for developers, manufacturers, and payers.

Clinicians and executives are navigating a complex environment in which precision immunologic targeting is maturing alongside sophisticated platform technologies such as nucleic acid-based constructs, viral vectors, and cell-based formulations. Meanwhile, regulatory authorities are refining evidentiary pathways for efficacy endpoints, real-world evidence integration, and adaptive approval mechanisms, which influences product development timelines and launch strategies. Taken together, these dynamics create both opportunity and responsibility: to design trials that demonstrate durable clinical benefit, to invest in scalable manufacturing, and to construct pricing and access models that reflect long-term value for patients and health systems.

Consequently, understanding therapeutic vaccines requires a multidimensional lens that spans indication-specific biology, platform capabilities, administration and distribution realities, and the stakeholder economics that determine adoption. This executive summary establishes that lens and prepares the reader for deeper analysis of transformative industry shifts, policy influences, segmentation implications, regional dynamics, competitive behavior, and actionable recommendations.

Major technological, regulatory, and manufacturing shifts are converging to redefine development pathways and commercial strategies for therapeutic vaccines

The therapeutic vaccines arena is being reshaped by a series of transformative shifts that alter how products are developed, manufactured, regulated, and commercialized. Technological acceleration in mRNA and self-amplifying RNA platforms, coupled with improved lipid nanoparticle delivery and refined antigen selection methods, is compressing timelines from discovery to first-in-human studies. At the same time, viral vector engineering and whole cell or dendritic cell strategies are expanding therapeutic reach into indications previously deemed intractable, particularly within oncology and complex infectious diseases. These platform advances are enabling more precise immune programming and combination strategies that pair vaccines with checkpoint inhibitors or targeted therapies to enhance efficacy.

Regulatory frameworks are adapting in parallel to accommodate adaptive trial designs, surrogate endpoints, and expedited pathways focused on meaningful clinical outcomes. Payers and health systems are increasingly demanding robust value demonstration, encompassing durability of response and downstream cost offsets, which is steering developers toward integrated health economics and outcomes research early in development. Additionally, manufacturing innovation-such as modular facilities, single-use bioprocessing, and decentralized production models-is reducing technical barriers to scale while raising expectations for supply chain resilience and quality assurance.

Taken together, these shifts are driving a new industry architecture in which cross-disciplinary collaboration, flexible regulatory engagement, and strategic manufacturing investments determine competitive differentiation. Organizations that align scientific ambition with pragmatic commercialization planning and stakeholder engagement will be best positioned to translate immunologic advances into meaningful patient impact and sustainable commercial outcomes.

How shifts in US tariff policy enacted in 2025 are influencing supply chain strategies, manufacturing localization, and procurement practices across therapeutic vaccine developers

The cumulative effect of tariff policy changes implemented in the United States in 2025 has introduced a new set of considerations for therapeutic vaccine stakeholders that extend across sourcing, manufacturing, and procurement decisions. Increased import tariffs on certain biologics inputs and components have elevated the cost of critical raw materials such as lipids for nanoparticle carriers, plasmid DNA production inputs, and specialty reagents used in viral vector manufacturing. As a result, supply chain planning has moved toward greater emphasis on supplier diversification and strategic inventory management to mitigate price volatility and potential shipment disruptions.

In response to tariff-driven cost pressures, some developers have accelerated initiatives to localize manufacturing operations and qualify domestic contract development and manufacturing organizations to reduce exposure to cross-border duties. This shift has implications for capital allocation and lead-time management, as building or repurposing facilities requires significant operational planning. Moreover, procurement teams are re-evaluating sourcing strategies and total landed cost analyses to incorporate tariff implications alongside transportation, cold chain logistics, and regulatory compliance overhead.

Regulatory and commercial stakeholders are also adapting to these trade policy effects. Payers and contracting entities are scrutinizing cost inputs more closely, which reinforces the need for early health economic modeling and transparent supply cost narratives. Policy uncertainty has increased interest in multi-sourcing, strategic stockpiles for critical inputs, and collaborative risk-sharing agreements between developers and manufacturing partners. Ultimately, the 2025 tariff landscape underscores the importance of resilient supply chains, proactive procurement strategies, and policy-aware commercial planning to preserve program timelines and patient access.

Deep segmentation insights that connect indication biology, platform selection, administration routes, distribution channels, and end-user realities to strategic program design

Segment-specific dynamics drive differentiated clinical, regulatory, and commercial strategies across therapeutic vaccine programs, with indication, platform, administration route, distribution channel, and end-user considerations each shaping development choices. Based on indication, development focus varies widely: autoimmune diseases target conditions such as lupus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes where antigen-specific tolerance and immune modulation are priorities; cancer programs concentrate on tumor types including breast, cervical, colorectal, melanoma, and prostate cancer where neoantigen targeting and combination regimens are critical; infectious disease efforts prioritize pathogens such as CMV, hepatitis viruses, HIV, HPV, and influenza where sterilizing immunity or durable control are the central endpoints; and neurological disorder initiatives address Alzheimer's disease, amyotrophic lateral sclerosis, epilepsy, and Parkinson's disease where blood-brain barrier delivery and neuroinflammation modulation are key scientific hurdles.

Based on technology platform, the choice between dendritic cell approaches, DNA platforms (including plasmid constructs), peptide vaccines, RNA platforms (comprising mRNA and self-amplifying RNA), viral vectors (including adenovirus, lentivirus, and vaccinia virus), and whole cell formulations materially alters manufacturing, regulatory engagement, and clinical trial design. RNA platforms typically demand advanced cold chain and delivery technologies, DNA plasmid workflows emphasize high-quality plasmid production and transfection strategies, and viral vector modalities require containment, potency assays, and specialized viral vector analytics. Dendritic cell and whole cell approaches often necessitate individualized or semi-personalized manufacturing workflows and close coordination with clinical sites.

Based on administration route, intradermal, intramuscular, intravenous, and subcutaneous delivery choices influence patient experience, dosing schedules, and the logistical footprint required for outpatient or inpatient administration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies present distinct fulfillment, storage, and reimbursement considerations that affect launch planning and patient access pathways. Based on end user, clinics, hospitals, and research institutes differ in procurement processes, clinical capabilities, and infrastructure readiness for specialized administration or investigational product handling. Integrating these segmentation layers into program planning enables sponsors to tailor clinical protocols, manufacturing scale, commercial access strategies, and stakeholder engagement plans to the realities of each therapeutic context.

Region-specific dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape regulatory strategy, manufacturing decisions, and market access planning

Regional dynamics exert powerful influence over development priorities, regulatory strategy, and commercialization pathways, necessitating region-aware planning across the Americas, Europe Middle East and Africa, and Asia-Pacific markets. In the Americas, strong innovation ecosystems, robust venture and corporate investment, and established regulatory frameworks encourage rapid clinical development and public-private partnerships, while payer systems vary, prompting developers to design flexible evidence-generation plans that support diverse reimbursement models. The region also hosts significant manufacturing capacity and a dense network of contract development and manufacturing organizations, which supports efforts to localize production and reduce supply chain exposure.

The Europe, Middle East and Africa region presents a complex mosaic of regulatory agencies, health technology assessment processes, and access landscapes. In many European markets, stringent value demonstration and centralized or coordinated procurement mechanisms require early alignment with health technology assessment bodies and multi-country clinical strategies. Regulatory convergence initiatives alongside regional centers of excellence for clinical trials and manufacturing present opportunities for strategic partnerships, but developers must navigate diverse reimbursement timelines and pricing pressures.

The Asia-Pacific region combines rapid clinical trial enrollment capacity, emerging manufacturing scale, and variable regulatory maturity. Several jurisdictions are accelerating regulatory reforms to facilitate innovative therapies, while others maintain more conservative pathways that demand localized data. Cost-conscious payers and rapidly growing healthcare infrastructure in certain markets create both challenges and opportunities for differentiated market-entry strategies. For all regions, cross-border collaborations, regional manufacturing hubs, and adaptive regulatory engagement strategies can optimize clinical timelines, improve supply reliability, and enhance patient access outcomes.

How corporate strategies and partnerships among leading companies are aligning platform specialization with manufacturing scalability and payer-focused evidence generation

Competitive behavior and corporate strategy among key companies in the therapeutic vaccines ecosystem reflect diversification across platforms, targeted indication portfolios, and strategic partnerships that bridge research, manufacturing, and commercialization capabilities. Leading organizations are pursuing platform consolidation to leverage core R&D investments across multiple indications, while others specialize in niche modalities such as dendritic cell therapies or viral vector engineering to capture scientific differentiation. Cross-sector alliances between biotechnology companies, academic centers, and contract manufacturers are increasingly common, aimed at accelerating translational work and ensuring supply chain capacity for clinical and commercial scale.

Partnership models vary from early-stage collaborations that co-develop antigen constructs and delivery systems, to later-stage licensing or commercialization agreements that align global go-to-market strategies. Manufacturers and service providers are investing in modular and flexible capacity to support heterogeneous product types-ranging from nucleic acid constructs requiring tight cold chain to cell-based products requiring individualized processing. In addition, some companies are integrating digital health and patient support solutions into launch plans to simplify administration logistics, monitor outcomes, and demonstrate real-world value.

Competitive differentiation also stems from regulatory acumen and payer engagement. Firms that proactively build robust health economic dossiers, engage with regulators on adaptive evidence pathways, and deploy early access programs are better positioned to secure favorable reimbursement arrangements and rapid uptake. Collectively, company strategies are converging on the need for end-to-end capabilities that link scientific innovation with scalable manufacturing, regulatory foresight, and commercially viable access models.

Practical and prioritized actions for developers and manufacturers to secure supply resilience, streamline regulatory engagement, and prove long-term value to payers and patients

Industry leaders should adopt a set of actionable priorities that balance scientific ambition with operational resilience and payer-oriented evidence generation. First, diversify supplier networks for critical inputs and prioritize qualification of alternate manufacturers to mitigate trade-related and single-source risks. Investing in regional manufacturing capacity or strategic partnerships can reduce exposure to cross-border policy changes while shortening lead times for clinical and commercial supply.

Second, integrate health economics and outcomes research into development programs from early phases to ensure that clinical trial design captures endpoints meaningful to regulators and payers alike. Employ adaptive trial designs and real-world evidence strategies to accelerate regulatory engagement and facilitate coverage discussions. Third, align platform selection with realistic manufacturing and distribution pathways. For instance, RNA-based approaches should be matched with cold chain optimization and delivery innovations, whereas viral vector programs require specialized containment and potency testing regimes.

Fourth, pursue targeted collaborations that combine antigen discovery capabilities, delivery expertise, and commercial channel access. These partnerships can accelerate translational timelines while sharing cost and risk. Fifth, engage proactively with regulators and payers through transparent evidence plans, early scientific advice sessions, and value demonstration pilots. Finally, augment commercial readiness with patient-centric access programs, digital adherence tools, and tailored distribution models that reflect the administration route and end-user capabilities. By operationalizing these priorities, industry leaders can convert scientific breakthroughs into durable clinical benefit and sustainable market access.

A transparent and multi-method research approach that integrates literature synthesis, expert interviews, pipeline analysis, and supply chain diagnostics for robust insights

The research methodology underpinning this analysis employed a rigorous, multi-source approach to ensure validity, reliability, and relevance for strategic decision-makers. The process began with a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and industry white papers to establish a baseline understanding of scientific advances and regulatory precedents. This secondary research informed targeted primary engagement, which included structured interviews with clinical investigators, manufacturing experts, regulatory advisors, payer representatives, and supply chain specialists to capture practitioner perspectives and operational constraints.

In parallel, a systematic mapping of technology platforms, manufacturing workflows, and administration routes was conducted to identify critical dependency points and scalability considerations. Clinical pipeline analysis focused on trial design heterogeneity, endpoint selection, and combination therapy strategies, while supply chain diagnostics assessed raw material sourcing, cold chain vulnerabilities, and contract manufacturing capacity. Analytic techniques included thematic synthesis of qualitative data, cross-validation of stakeholder claims against regulatory documents and trial registries, and scenario-based impact assessment to evaluate policy and tariff sensitivities.

Finally, findings were triangulated through iterative expert review and validation sessions to ensure interpretation robustness and practical applicability. This blended methodology balances depth of clinical and technical insight with pragmatic considerations of manufacturing, regulatory, and commercial viability, producing an evidence-informed foundation for the recommendations presented herein.

A conclusive synthesis emphasizing the need to align scientific innovation with manufacturing resilience, payer engagement, and segmented program planning for real-world impact

In conclusion, therapeutic vaccines occupy a pivotal role in the future of precision medicine, offering the prospect of durable disease control across oncology, infectious diseases, autoimmune conditions, and select neurological disorders. Scientific progress in nucleic acid platforms, viral vectors, and cell-based approaches, combined with evolving regulatory pathways and manufacturing innovations, has created a fertile environment for meaningful clinical advances. However, realizing that potential depends on proactive management of supply chain resilience, early alignment with payers and regulators, and careful orchestration of manufacturing and distribution strategies to support diverse administration routes and end-user settings.

Stakeholders who integrate segmented program planning-aligning indication-specific biology with platform capabilities, administration logistics, and distribution channels-will be well-positioned to navigate clinical complexity and access challenges. Moreover, the trade policy shifts witnessed in 2025 underscore the strategic value of supplier diversification and regional manufacturing planning. By coupling scientific rigor with operational foresight and payer-focused evidence generation, developers can translate immunologic innovation into sustainable therapeutic solutions that deliver measurable benefit to patients and health systems alike.

The strategic imperative is clear: to convert technological promise into real-world impact, organizations must synchronize R&D priorities with pragmatic manufacturing investments, adaptive regulatory engagement, and thoughtful market-access planning that ensures therapies reach the patients who need them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of mRNA-based therapeutic vaccine platforms targeting personalized tumor neoantigens to enhance immunogenicity
  • 5.2. Integration of novel adjuvant delivery systems using nanoparticle carriers to boost vaccine-induced immune responses
  • 5.3. Development of combination therapies pairing therapeutic vaccines with immune checkpoint inhibitors to overcome tumor resistance
  • 5.4. Adoption of artificial intelligence in epitope prediction workflows to accelerate vaccine candidate design
  • 5.5. Expansion of off-the-shelf allogeneic dendritic cell vaccines leveraging CRISPR gene editing for antigen loading
  • 5.6. Regulatory pathways evolving for accelerated approval of therapeutic vaccines under IND and BLA frameworks
  • 5.7. Investigation of heterologous prime-boost strategies to improve durability and breadth of vaccine-mediated immunity
  • 5.8. Increasing investment in therapeutic vaccine pipelines from big pharma through strategic biotech partnerships

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Therapeutic Vaccines Market, by Indication

  • 8.1. Autoimmune Diseases
    • 8.1.1. Lupus
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Rheumatoid Arthritis
    • 8.1.4. Type 1 Diabetes
  • 8.2. Cancer
    • 8.2.1. Breast Cancer
    • 8.2.2. Cervical Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Melanoma
    • 8.2.5. Prostate Cancer
  • 8.3. Infectious Diseases
    • 8.3.1. CMV
    • 8.3.2. Hepatitis
    • 8.3.3. HIV
    • 8.3.4. HPV
    • 8.3.5. Influenza
  • 8.4. Neurological Disorders
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Amyotrophic Lateral Sclerosis
    • 8.4.3. Epilepsy
    • 8.4.4. Parkinson's Disease

9. Therapeutic Vaccines Market, by Technology Platform

  • 9.1. Dendritic Cell
  • 9.2. DNA
    • 9.2.1. Plasmid
  • 9.3. Peptide
  • 9.4. RNA
    • 9.4.1. mRNA
    • 9.4.2. Self Amplifying RNA
  • 9.5. Viral Vector
    • 9.5.1. Adenovirus
    • 9.5.2. Lentivirus
    • 9.5.3. Vaccinia Virus
  • 9.6. Whole Cell

10. Therapeutic Vaccines Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Subcutaneous

11. Therapeutic Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Therapeutic Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Therapeutic Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Therapeutic Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Therapeutic Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Moderna, Inc.
    • 16.3.5. BioNTech SE
    • 16.3.6. Bavarian Nordic A/S
    • 16.3.7. Agenus Inc.
    • 16.3.8. Inovio Pharmaceuticals, Inc.
    • 16.3.9. Dendreon Pharmaceuticals LLC
    • 16.3.10. GeoVax Labs, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA THE